BOOM

Trending Searches

    SUPPORT
    BOOM

    Trending News

      • Fact Check 
        • Fast Check
        • Politics
        • Business
        • Entertainment
        • Social
        • Sports
        • World
      • Law
      • Explainers
      • News 
        • All News
      • Decode 
        • Impact
        • Scamcheck
        • Life
        • Voices
      • Media Buddhi 
        • Digital Buddhi
        • Senior Citizens
        • Videos
      • Web Stories
      • BOOM Research
      • BOOM Labs
      • Deepfake Tracker
      • Videos 
        • Facts Neeti
      • Home-icon
        Home
      • About Us-icon
        About Us
      • Authors-icon
        Authors
      • Team-icon
        Team
      • Careers-icon
        Careers
      • Internship-icon
        Internship
      • Contact Us-icon
        Contact Us
      • Methodology-icon
        Methodology
      • Correction Policy-icon
        Correction Policy
      • Non-Partnership Policy-icon
        Non-Partnership Policy
      • Cookie Policy-icon
        Cookie Policy
      • Grievance Redressal-icon
        Grievance Redressal
      • Republishing Guidelines-icon
        Republishing Guidelines
      • Fact Check-icon
        Fact Check
        Fast Check
        Politics
        Business
        Entertainment
        Social
        Sports
        World
      • Law-icon
        Law
      • Explainers-icon
        Explainers
      • News-icon
        News
        All News
      • Decode-icon
        Decode
        Impact
        Scamcheck
        Life
        Voices
      • Media Buddhi-icon
        Media Buddhi
        Digital Buddhi
        Senior Citizens
        Videos
      • Web Stories-icon
        Web Stories
      • BOOM Research-icon
        BOOM Research
      • BOOM Labs-icon
        BOOM Labs
      • Deepfake Tracker-icon
        Deepfake Tracker
      • Videos-icon
        Videos
        Facts Neeti
      Trending Tags
      TRENDING
      • #Operation Sindoor
      • #Pahalgam Terror Attack
      • #Narendra Modi
      • #Rahul Gandhi
      • #Waqf Amendment Bill
      • #Arvind Kejriwal
      • #Deepfake
      • #Artificial Intelligence
      • Home
      • Coronavirus
      • Is One Dose Of Covishield Enough To...
      Coronavirus

      Is One Dose Of Covishield Enough To Fight COVID? What Experts Say

      The efficacy of a single dose of Covishield against the B.1.617.2 variant which is prevalent in India was found to be close to 33%.

      By - Shachi Sutaria |
      Published -  1 Jun 2021 12:09 PM IST
    • Boomlive
      Is One Dose Of Covishield Enough To Fight COVID? What Experts Say

      In an effort to 'fine-tune' vaccination strategy that aims to scale up daily administered doses in India, the Centre plans to test the effect of one dose of Covishield instead of the prescribed two doses on its citizens, government sources told several news organisations. Earlier reports had already suggested that the Centre plans to study a mix-and-match regimen-- mixing different vaccines.

      BOOM spoke to three biologists who all agreed that there is not enough data to substantiate implementing a single-dose regimen in the country but differed on their opinions of conducting studies for the same.

      Vaccines such as Johnson and Johnson as well as the Sputnik that use the same viral vector technology for vaccine-making as Astrazeneca are single dose. So, the government believes that the Oxford-AstraZeneca vaccine could also be equally effective with only one dose. However, a study carried out in the UK by scientists at Public Health England found that a single dose of Covishield was only 33% effective against the B.1.617.2 variant that is rampant in India. At two doses, the vaccine was doubly effective as it showed 60% efficacy against this variant.

      Taking a note of this study, Anurag Agarwal, Director, Council of Scientific and Industrial Research (CSIR)-Institute of Genomics and Integrative Biology, had told The Hindu that health workers, frontline workers and the people in the elderly community will need to receive two doses of the vaccine.

      Also Read:Vaccinated But No Antibodies? It's Not The Only Immunity Against COVID

      Not Enough Data

      BOOM spoke to Dr. Sharvan Sehrawat, immunologist, Indian Institute of Scientific Education and Research (IISER), Mohali to understand the relevance of using a one-shot vaccine in India.

      "One dose is going to give some kind of immunity. Even the UK tried to prioritise vaccinating its whole population by giving everyone a single dose first, and it worked. We do not have enough data, but it is quite possible that the same regime might work in India," Sehrawat opined.

      Dr. N K Ganguly, former director-general, Indian Council of Medical Research and Dr. Sankaran Krishnaswamy, co-founder of Indian Scientists Response to COVID-19, and retired Professor of Bioinformatics, Madurai Kamraj University agreed that there is not enough data but both believed that following a two-dose regime will produce better outcomes.

      Also Read:CoWin Necessary From Logistical And Management Point Of View: RS Sharma

      Is This Due To Vaccine Shortage?

      Dr. Ganguly highlighted that both the Johnson and Johnson viral vector vaccine and the Sputnik Light vector vaccine are single-dose vaccines and as they use similar technology to the Oxford-AstraZeneca vaccine, it is plausible to implement the same rule. However, he said that there is not enough data.

      "A single dose has only shown 30-40% efficacy while that increased to 80% after the second dose. The UK followed a single dose regime for a short period as it was facing a shortage of vaccine doses and wanted to vaccinate a larger proportion of its population. Both Sputnik light and Johnson and Johnson have data backing their single-dose usage," explained Dr Ganguly.

      The former director-general of ICMR said that unless India has data supporting its move or has a valid reason for it, such as vaccine shortage, the double dose regime should continue.

      Dr Krishnaswamy wanted to know if the government is going to register a trial with the Clinical Trials Registry for checking a single-dose efficacy. India has so far only relied on the results carried out in the UK for bringing about changes in the dosage or changing the gap between the duration of the two doses.

      "First, they keep changing the duration for taking the vaccines, and now if they are planning this move, it shows that they did not place enough orders of the vaccine in the first place. If you are looking to vaccinate your adult population, the government should have arranged for at least 1.2 times the population. Some countries have even ordered doses 5 times the population," said Dr Krishnaswamy.

      Also Read: "Wake Up And Smell The Coffee": Supreme Court To Centre On Vaccine Policy

      How Will This Affect Breakthrough Infections?

      If a person gets infected after receiving even one dose of the vaccine, it is considered a 'breakthrough infection'. According to government data as of May 18, 23,940 people in India got the infection after taking Covaxin -- 0.13 per cent of the total vaccinated so far. Of these, 18,427 were infected after the first dose, while 5,513 were infected after the second dose.

      Similarly, 1,19,172 breakthrough infections have been reported after taking Covishield, which is 0.07 per cent of the administered doses. Of these, 84,198 got infected after the first dose, while 34,874 got infected after the second dose.

      Both Sehrawat and Ganguly agreed that breakthrough infections could increase if a single dose vaccine is administered. Sehrawat, however, added that these cases would have milder bouts of COVID-19 as compared to not being vaccinated at all.


      Tags

      covishieldOxford AstraZeneca VaccineCOVID-19
      Read Full Article
      Next Story
      Our website is made possible by displaying online advertisements to our visitors.
      Please consider supporting us by disabling your ad blocker. Please reload after ad blocker is disabled.
      X

      Subscribe to BOOM Newsletters

      👉 No spam, no paywall — but verified insights.

      Please enter a Email Address
      Subscribe for free!

      Stay Ahead of Misinformation!

      Please enter a Email Address
      Subscribe Now🛡️ 100% Privacy Protected | No Spam, Just Facts
      By subscribing, you agree with the Terms & conditions and Privacy Policy connected to the offer

      Thank you for subscribing!

      You’re now part of the BOOM community.

      Or, Subscribe to receive latest news via email
      Subscribed Successfully...
      Copy HTMLHTML is copied!
      There's no data to copy!